Patent ID: 8965709
Filing Date: 2015-02-24
Classification: A61K,A61P,C12Q,G01N

Abstract:
1. A method of treating an individual having Growth Hormone Deficiency (GHD), the method comprising the steps of: a) identifying insulin-like growth factor standard deviation score (IGF-I SDS) at treatment baseline (“IGF-I_SDS_B”); b) setting the treatment adherence in percent of expected doses/planned doses during the first month of treatment (“adherence”); c) measuring the weight standard deviation score (SDS) at treatment baseline (“bl_wt SDS”); d) setting the average growth hormone dose prescribed in μg/kg bodyweight/day (“dose”); e) providing the age in years (“age”); f) calculating the predicted IGF-I SDS after one month of treatment with growth hormone as IGF-I_SDS g) identifying the individual as a low responder if IGF-I SDS level change at one month compared to the IGF-I_SDS_B is less than 0.81, identifying the individual as a high responder if IGF-I SDS level change at one month compared to the IGF-I_SDS_B is more than 1.91 and identifying the individual as an intermediate responder if IGF-I SDS level change at one month compared to the IGF-I_SDS_B is 0.81 to 1.91; and h) administering growth hormone to the individual identified as a low responder or as a high responder.